Guidelines for clinical application of platinum drugs in breast cancer (2023 edition).
10.3760/cma.j.cn112152-20230427-00186
- Collective Name:Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Clinical applications;
Expert consensus;
Platinum drugs
- MeSH:
Female;
Humans;
Breast Neoplasms/pathology*;
Platinum/therapeutic use*;
Consensus;
China
- From:
Chinese Journal of Oncology
2023;45(12):1018-1031
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is the most common malignant tumor in women around the world, and it is also a common cause of death in female patients with malignant tumors in China, which seriously harms women's health. At present, with the application of comprehensive treatment approaches, breast cancer has become one of the most effective solid tumors. Platinum drugs are widely used in malignant tumors, and they are also commonly used as effective chemotherapeutic drugs for breast cancer. To regulate the application of platinum drugs in breast cancer, the experts from Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association, discuss and approve the "Guidelines for clinical application of platinum drugs in breast cancer (2023 edition)" . This guideline is developed from the "Expert consensus on the clinical application of platinums in advanced breast cancer (2020 version)" , which is updated from the latest evidence based on breast cancer at home and abroad, for platinum drugs in breast cancer clinical use, application scheme, efficacy analysis and treatment of adverse effects. This guideline aims to guide clinicians to use drugs rationally, and to further standardize the diagnosis and treatment.
